| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,095,971,000 |
| Market
Cap: |
17.81(B) |
| Last
Volume: |
13,820,198 |
Avg
Vol: |
10,623,119 |
| 52
Week Range: |
$7.2 - $16 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ-100 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Teva Pharmaceutical Industries is a pharmaceutical company. Co. operates through three segments: North America, which includes the U.S. and Canada; Europe, which includes the European Union and certain other European countries; and International Markets, which includes all countries in which Co. operates other than those in Co.'s North America and Europe segments. Co.'s products include: AUSTEDO; AJOVY (anti calcitonin gene-related peptide); COPAXONE; BENDEKA and TREANDA; ProAir HFA; ProAir RespiClick; QVAR; QVAR RediHaler; ProAir Digihaler; ArmonAir Digihaler; AirDuo Digihaler; BRALTUS®; CINQAIR/CINQAERO; and AirDuo RespiClick.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
645,577 |
677,343 |
767,191 |
1,433,490 |
| Total Sell Value |
$8,581,650 |
$8,974,605 |
$9,773,842 |
$16,030,825 |
| Total People Sold |
7 |
8 |
8 |
11 |
| Total Sell Transactions |
13 |
14 |
17 |
32 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcclellan Michael James |
EVP, Chief Financial Officer |
• – – |
2019-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
660 |
12,990 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
943 |
943 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2019-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,012 |
17,106 |
|
- |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2019-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,297 |
1,297 |
|
- |
|
| Dethlefs Sven |
EVP Global Marketing&Portfolio |
• – – |
2019-03-12 |
4 |
AS |
$15.67 |
$10,142 |
D/D |
(647) |
8,602 |
|
- |
|
| Dethlefs Sven |
EVP Global Marketing&Portfolio |
• – – |
2019-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,191 |
9,249 |
|
- |
|
| Ogrady Brendan P. |
EVP, North America Commercial |
• – – |
2019-03-12 |
4 |
S |
$15.67 |
$11,568 |
D/D |
(738) |
1,388 |
|
- |
|
| Ogrady Brendan P. |
EVP, North America Commercial |
• – – |
2019-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
738 |
2,126 |
|
- |
|
| Stark David Matthew |
Exec. VP Chief Legal Officer |
• – – |
2019-03-12 |
4 |
AS |
$15.82 |
$38,664 |
D/D |
(2,444) |
2,974 |
|
- |
|
| Stark David Matthew |
Exec. VP Chief Legal Officer |
• – – |
2019-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,444 |
5,418 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-12 |
4 |
S |
$15.67 |
$14,938 |
D/D |
(953) |
0 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
953 |
953 |
|
- |
|
| Nazzi Gianfranco |
EVP, Growth Markets Commercial |
• – – |
2019-03-12 |
4 |
S |
$15.69 |
$5,099 |
D/D |
(325) |
8,450 |
|
- |
|
| Nazzi Gianfranco |
EVP, Growth Markets Commercial |
• – – |
2019-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
883 |
8,775 |
|
- |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2019-03-12 |
4 |
S |
$15.69 |
$11,218 |
D/D |
(715) |
0 |
|
- |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2019-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
715 |
715 |
|
- |
|
| Nazzi Gianfranco |
EVP, Growth Markets Commercial |
• – – |
2019-03-04 |
4 |
S |
$16.88 |
$8,645 |
D/D |
(512) |
7,892 |
|
- |
|
| Ogrady Brendan P. |
EVP, North America Commercial |
• – – |
2019-03-04 |
4 |
S |
$16.88 |
$19,686 |
D/D |
(1,166) |
1,388 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2019-03-04 |
4 |
AS |
$16.88 |
$6,905 |
D/D |
(409) |
16,094 |
|
- |
|
| Fridriksdottir Hafrun |
Executive VP, Global R&D |
• – – |
2019-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,165 |
16,503 |
|
- |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2019-03-04 |
4 |
S |
$16.88 |
$35,423 |
D/D |
(2,098) |
0 |
|
- |
|
| Dethlefs Sven |
EVP Global Marketing&Portfolio |
• – – |
2019-03-04 |
4 |
AS |
$16.88 |
$10,231 |
D/D |
(606) |
8,058 |
|
- |
|
| Mcclellan Michael James |
EVP, Chief Financial Officer |
• – – |
2019-03-04 |
4 |
AS |
$16.88 |
$6,129 |
D/D |
(363) |
12,330 |
|
- |
|
| Griffin Deborah A |
Chief Accounting Officer |
• – – |
2019-03-04 |
4 |
S |
$16.88 |
$69,340 |
D/D |
(4,107) |
0 |
|
- |
|
| Nazzi Gianfranco |
EVP, Growth Markets Commercial |
• – – |
2019-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,399 |
8,404 |
|
- |
|
521 Records found
|
|
Page 17 of 21 |
|
|
0.25 (1.56%) 
